1- I view the current trading pattern as accumulation by those not yet having a core position.
2- The coming earning cc on Oct 30 will be the key driver.
3- THOR, with the HM3, PHP, improved Centimag, FILVAS, DuraHeart II, now has the means to get to the next level within the HUGE global arena of MCSD.
4- Furthermore, the FDA provides a pseudo monopoly. Samsung can't design a copy here as it did to AAPL. That's a HUGE advantage no other industry has.
5- THOR has recently over-burdened itself with the HUGE pipeline. For example, taking on the DuraHeart has resulted in an additional $7 million expense. If THOR can still show accelerated earnings despite the cost of the pipeline, I can see triple digits.
6- I am not adding to my position until Oct 30. I assume those that have more insight, such as Analysts directly talking to MDs, are willing to add stock in the $38 region but will not aggressively purchase shares at the $40 handle UNLESS it's an initial core holding, i.e., those not having a position.
7- I see the Aspirin requirement of 161 mg to 325 mg DAILY of the HVAD and probably the MVAD as a HUGE disadvantage for HTWR. As you know in Europe clinical prospective and retrospective studies, a daily aspirin of the above magnitude can produce a myriad of problems including accelerated macular degeneration, asymptomatic micro-brain-bleeding, gastrointestinal bleeding, etc., etc. Simply put, HTWR will become an also ran when the HM3 emerges in Q1 2014 in clinical trials.